Pharmacodynamic and Pharmacokinetic Features of Cabergoline

  title={Pharmacodynamic and Pharmacokinetic Features of Cabergoline},
  author={Ruggero G. Fariello},
  • R. Fariello
  • Published 2012
  • Biology, Medicine, Psychology
  • Drugs
SummaryThe appearance of late motor complications is the major drawback of long term levodopa therapy in patients with Parkinson’s disease. Although disease progression may be a factor in the aetiology of these complications, unfavourable properties of levodopa may promote their development. These include competition with amino acids for gastrointestinal absorption and passage through the blood-brain barrier; and a short duration of action with a rapid peak plasma concentration and rapid… 

Pharmacological therapy of Parkinson's disease: current options and new avenues.

The aim of this review is to summarize the features of drugs currently used in the pharmacotherapy of Parkinson's disease, with a look at their beneficial effects and limitations.

Altered Pain Processing Associated with Administration of Dopamine Agonist and Antagonist in Healthy Volunteers

The results support the notion that D2 receptor neurotransmission has a role in the top-down modulation of pain and that pain sensitivity and unpleasantness were not changed by D2R modulation.

Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin

Thyroid hormones and prolactin-lowering drugs (e.g. cabergoline, aripiprazole) are candidate drugs to be tested in repurposing clinical trials aiming to improve the cognitive abilities of patients with major mood disorder and schizophrenia.

Dopamine D2 agonist affects visuospatial working memory distractor interference depending on individual differences in baseline working memory span

Results showed greater interference from distractors under cabergoline, particularly for individuals with higher baseline dopamine (indicated by WM span), which support computational theories of striatal D1–D2 function during WM encoding and distractor-filtering and provide new evidence for interactive cortico-striatal systems that support VSWM capacity and their dependence on WM span.



Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Pergolide would appear to be at least as useful as other dopamine agonists such as bromocriptine or lisuride for the management of patients with Parkinson's disease when administered in combination with levodopa.

Cabergoline in the treatment of early parkinson's disease

The results of this study indicate that cabergoline treatment for up to 1 year is only marginally less effective than levodopa in the proportion of patients who can be treated in monotherapy.

Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.

It is confirmed that cabergoline is effective in the management of PD motor fluctuations without modifying L-dopa and 3-OMD pharmacokinetics.

A Rationale for Dopamine Agonists as Primary Therapy for Parkinson’s Disease

  • C. Olanow
  • Psychology, Medicine
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 1992
In this way symptomatic control is not compromised on theoretical grounds, but the cumulative levodopa dose is minimized in an effort to reduce the likelihood of free radical formation with their potential adverse consequences on disease progression.

Motor complications associated with chronic levodopa therapy in Parkinson's disease.

Patients with complex fluctuations are the least likely to improve with slow-release levodopa preparations, and drugs capable of providing a stable dopaminergic stimulation should be particularly useful for preventing the development of motor complications in patients not yet treated.

Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued

The results imply that combination therapy with bromocriptine should be preferred over L-Dopa monotherapy from the very beginning.

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

Interference with absorption oflevodopa by food and by competition between large neutral amino acids and levodopa for transport from plasma to the brain may be partly responsible for the fluctuating clinical response in patients with Parkinson's disease.

Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study

Results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons, the first anti-Parkinson drug having such a property.

Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids.

The plasma concentrations at the steady state in a patient with Parkinson's disease who had received the drug at single oral daily doses of 3, 5 and 7 mg were determined using the assay, validated in terms of reproducibility, precision and accuracy.

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

It is concluded that cabergoline is an effective adjunct to levodopa for the treatment of PD.